Of Monsters and Men
By George Estreich, Biopolitical Times guest contributor
| 11. 29. 2012
To be interested in questions of human enhancement, while also being a sucker for Hollywood blockbusters about superheroes, makes for an odd movie experience. Immersed in a fictional world both saved and threatened by the enhanced, you’re aware of the world you’ve just paid to escape. You feel doubled, like the superheroes themselves—though since you’re sitting on the couch and not saving the world, the division is less profound. You don’t have secret powers, just cognitive dissonance; your perception, not your identity, is split.
A few nights ago, I watched The Amazing Spider-Man on Blu-Ray. (Warning: many spoilers ensue.) The movie reboots the franchise that began in 2002, and this time around, the genetic enhancement of human beings is far more central to the plot. Just as in the first series, the high school student Peter Parker, bitten by a genetically modified spider, develops superpowers; but this time around, the spider comes from a corporation whose business model depends on “cross-species genetics,” and Peter’s nemesis—the scientist Curtis Connors, once the research partner of Peter’s deceased father—is a man with one...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...